IMMUNE CHECKPOINT INHIBITOR
Clinical trials for IMMUNE CHECKPOINT INHIBITOR explained in plain language.
Never miss a new study
Get alerted when new IMMUNE CHECKPOINT INHIBITOR trials appear
Sign up with your email to follow new studies for IMMUNE CHECKPOINT INHIBITOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis study tests a special radiation method called lattice radiation therapy (LRT) combined with immunotherapy for people with advanced solid tumors that have stopped responding to standard treatments. LRT delivers high doses of radiation to specific spots inside the tumor while …
Matched conditions: IMMUNE CHECKPOINT INHIBITOR
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 17, 2026 02:08 UTC
-
New combo therapy aims to improve survival in advanced nose cancer
Disease control Recruiting nowThis study tests whether adding low-dose radiation and an immunotherapy drug (cadonilimab) to standard chemotherapy can help people with advanced nasopharyngeal cancer live longer without the cancer coming back. About 380 adults aged 18-70 with newly diagnosed, advanced-stage dis…
Matched conditions: IMMUNE CHECKPOINT INHIBITOR
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Radiotherapy combo may tame kidney cancer resistant to immunotherapy
Disease control Recruiting nowThis study is for people with kidney cancer that got worse after immunotherapy. It tests a special type of radiotherapy (multimodal radiotherapy) to see if it can control the cancer better. About 35 participants will receive this treatment, and doctors will monitor tumor shrinkag…
Matched conditions: IMMUNE CHECKPOINT INHIBITOR
Phase: PHASE2 • Sponsor: Jinling Hospital, China • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New combo therapy aims to stop liver cancer from coming back
Disease control Recruiting nowThis study tests whether combining radiation with an immunotherapy drug (sintilimab) works better than a standard procedure (TACE) to keep liver cancer from returning after surgery. It includes 286 adults whose tumors were removed but had narrow margins and high-risk features. Th…
Matched conditions: IMMUNE CHECKPOINT INHIBITOR
Phase: PHASE3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
Blood test may predict immunotherapy success in advanced cancers
Knowledge-focused Recruiting nowThis study is observing 50 adults with advanced cancers (like lung, breast, or colon) who are starting immunotherapy. Researchers want to see if changes in a blood marker called ctDNA can predict early on whether the treatment is working. They will also look at other tumor marker…
Matched conditions: IMMUNE CHECKPOINT INHIBITOR
Sponsor: Gene Solutions • Aim: Knowledge-focused
Last updated May 17, 2026 02:08 UTC